EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Transmetalation in Cancer Pharmacology

Mahendiran Dharmasivam iD, Busra Kaya iD

International Journal of Molecular Sciences · 14.11.2025 · 26 (22) · 11008

DOI: 10.3390/ijms262211008 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 14.11.2025. Verfasst von Mahendiran Dharmasivam und 1 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Biomedicine and Glycomics, Griffith University, Southport, QLD 4215, Australia. Hauptthemen laut MEDLINE: Neoplasms, Coordination Complexes, Antineoplastic Agents, Metals. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 241 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council, NHMRC MRFF, Thrasher Research Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Transmetalation, the exchange of metal ions between coordination complexes and biomolecules, has emerged as a powerful design lever in cancer metallopharmacology. Using thiosemicarbazones (TSCs) as a unifying case study, we show how redox-inert carrier states such as zinc(II) or gallium(III) can convert in situ into redox-active copper(II) or iron(III/II) complexes within acidic, metal-rich lysosomes. This conditional activation localizes reactive oxygen species (ROS) generation and iron deprivation to tumor cells. We critically compare redox-active and redox-inert states, delineating how steric and electronic tuning, backbone rigidity, and sulfur-to-selenium substitution govern exchange hierarchies and kinetics. We further map downstream consequences for metal trafficking, lysosomal membrane permeabilization, apoptosis, and ferroptosis. Beyond TSCs, iron(III)-targeted transmetalation from titanium(IV)-chelator “chemical transferrin mimetics” illustrates a generalizable Trojan horse paradigm. We conclude with translational lessons, including mitigation of hemoprotein oxidation via steric shielding, stealth zinc(II) prodrugs, and dual-chelator architectures and outline biomarker, formulation, and imaging strategies that de-risk clinical development. Collectively, these insights establish transmetalation as a central therapeutic principle. We also highlight open challenges such as quantifying in-cell exchange kinetics, predicting speciation under non-equilibrium conditions, and rationally combining these agents with existing therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsCoordination ComplexesAntineoplastic AgentsMetalsHumansOxidation-ReductionLysosomesAnimalsReactive Oxygen SpeciesIronThiosemicarbazones

Stichwörter der Autor:innen

copper/iron pharmacologyferroptosislysosomal targetingreactive oxygen speciesthiosemicarbazonetransmetalation

Substanzen

Coordination ComplexesAntineoplastic AgentsReactive Oxygen SpeciesIronThiosemicarbazonesMetals

Autor:innen und Institutionen

  • Institute for Biomedicine and Glycomics, Griffith University, Southport, QLD 4215, Australia.

ORCID-Profile: Mahendiran Dharmasivam, Busra Kaya

Förderung

  • National Health and Medical Research Council
  • NHMRC MRFF
  • Thrasher Research Fund

Zitieren

APA

Dharmasivam, M., & Kaya, B. (2025). Transmetalation in Cancer Pharmacology. International Journal of Molecular Sciences, 26(22), 11008. https://doi.org/10.3390/ijms262211008

Vancouver

Dharmasivam M, Kaya B. Transmetalation in Cancer Pharmacology. International Journal of Molecular Sciences. 2025;26(22):11008. doi:10.3390/ijms262211008

BibTeX
@article{Dharmasivam2025,
  author = {Dharmasivam, Mahendiran and Kaya, Busra},
  title = {Transmetalation in Cancer Pharmacology},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {22},
  pages = {11008},
  doi = {10.3390/ijms262211008}
}
Kostenlos starten →